European sub-registry of chronic myelogenous leukemia (CML) patients (pts) in failure after imatinib therapy (IFP): Rationale, study design and current enrollment.

被引：0
|
作者：
Guilhot, Joelle
Tartarin, Florence
Pfirmann, Markus
Nagler, Arnon
Nicolini, Franck
Rousselot, Philippe
Porkka, Kimmo
Ossenkoppele, Gert
Stentoft, Jesper
Cervantes, Francisco
Rosti, Gianantonio
Thaler, Josef
le Coutre, Philipp
Hasford, Joerg
Hehlmann, Rudiger
Guilhot, Francois
机构：
[1] CHU La Miletrie, Clin Res Ctr, Poitiers, France
[2] Univ Innsbruck, A-6020 Innsbruck, Austria
[3] Charite Univ Med Berlin, Berlin, Germany
[4] Univ Heidelberg, D-6800 Mannheim, Germany
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4764
引用
收藏
页码：274B / 274B
页数：1
相关论文
共 50 条
  • [1] EUROPEAN SUB-REGISTRY OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS (PTS) IN FAILURE AFTER IMATINIB THERAPY (IFP): RATIONALE, STUDY DESIGN AND CURRENT STATUS. A STUDY FROM THE EUROPEAN LEUKEMIANET (ELN)
    Guilhot, J.
    Tartarin, F.
    Hochhaus, A.
    Saussele, S.
    Nicolini, F.
    Rosti, G.
    Steegman, J. L.
    Sacha, T.
    Le Coutre, P.
    Nagler, A.
    Abruzzese, F.
    Heim, D.
    Clark, R.
    Stentoft, J.
    Faber, E.
    Porkka, K.
    Cervantes, F.
    Hoeglund, M.
    O'Brien, S.
    Thaler, J.
    Turkina, A.
    Ossenkoppele, G.
    Zackova, D.
    Klamova, H.
    Gambacorti, C.
    Pfirrmann, M.
    Hasford, J.
    Hehlmann, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 60 - 61
  • [2] Pleural effusion in patients (pts) with chronic myelogenous leukemia (CML) treated with dasatinib after imatinib failure.
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop M.
    Munden, Reginald
    Talpaz, Moshe
    Bruzzi, John
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Nicaise, Claude
    Cortes, Jorge
    BLOOD, 2006, 108 (11) : 614A - 614A
  • [3] Subcutaneous (SC) homoharringtonine (HHT) for patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) after imatinib mesylate failure.
    Quintas-Cardama, A
    Cortes, J
    Verstovsek, S
    Laddie, N
    Estrov, Z
    Kantarjian, H
    BLOOD, 2005, 106 (11) : 290B - 290B
  • [4] Recombinant human erythropoietin (rHuEPO) is effective for the treatment of anemia associated with imatinib therapy in patients (PTS) with chronic phase chronic myelogenous leukemia (CML).
    Cortes, J
    O'Brien, S
    Quintas-Cardama, A
    Ault, P
    Giles, F
    Shan, JQ
    Rios, MB
    Kantarjian, H
    BLOOD, 2003, 102 (11) : 911A - 911A
  • [5] Phase I study of lonafarnib (SCH66336) in combination with imatinib for patients (pts) with chronic myeloid leukemia (CML) after failure to imatinib.
    Cortes, J
    O'Brien, S
    Verstovsek, S
    Daley, G
    Koller, C
    Ferrajoli, A
    Pate, O
    Faderl, S
    Ravandi-Kashani, F
    Talpaz, M
    Zhu, YL
    Statkevich, P
    Sugrue, M
    Kantarjian, H
    BLOOD, 2004, 104 (11) : 288A - 288A
  • [6] Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
    Cortes, Jorge
    Quintas-Cardama, Alfonso
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Jones, Dan
    Faderl, Stefan
    Ebarb, Theresa
    Giles, Francis
    Thomas, Deborah
    Kantarjian, Hagop
    CANCER, 2007, 110 (09) : 2000 - 2006
  • [7] Results of imatinib mesylate (STI571) therapy in patients (pts) with chronic myelogenous leukemia (CML) in relapse after allogeneic stem cell transplantation (allo SCT).
    Kantarjian, HM
    O'Brien, S
    Cortes, J
    Giralt, S
    Rios, MB
    Shan, J
    Giles, F
    Thomas, D
    Faderl, S
    de Lima, M
    Arlinghaus, RB
    Garcia-Manero, G
    Issa, JP
    Resta, D
    Capdeville, R
    Talpaz, M
    BLOOD, 2001, 98 (11) : 137A - 137A
  • [8] Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure
    Mueller, M. C.
    Branford, S.
    Radich, J.
    Kim, D. W.
    Martinelli, G.
    Saglio, G.
    Hughes, T.
    Shou, Y.
    Weitzman, A.
    Baccarani, M.
    Hochhaus, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Phase I study of nilotinib in patients (pts) from Japan with imatinib-resistant Ph plus chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL)
    Tojyo, A.
    Miyazaki, Y.
    Usui, N.
    Kobyashi, Y.
    Okamoto, S.
    Oyashiki, K.
    Nishimura, M.
    Okada, M.
    Natori, H.
    Tanii, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] THE EFFICACY OF IMATINIB MESYLATE TREATMENT PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA PH' POSITIVE (CML) REFRACTORY TO PREVIOUSLY INTERFERON THERAPY (CML) - THE OWN POLISH STUDY REPORT
    Ceglarek, B.
    Konopka, L.
    Warzocha, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 577 - 578
12345